细菌治疗中的进展和优化策略,用于治疗炎症性肠病
Yang Li1,2, Xiao-Meng Li2, Hao-Yu Duan1
1General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, China.
Frontiers in immunology
|May 23, 2024
概括
菌体显示出通过调节肠道微生物群来治疗炎症性肠病 (IBD) 的前景. 封装和向输送方法是改善IBD患者菌体治疗稳定性和疗效的关键.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 生物技术是生物技术.
背景情况:
- 目前的炎症性肠病 (IBD) 治疗方法有限,缺乏完整的治疗方法,并引起副作用.
- 肠道微生物群显著影响IBD的发病过程.
- 菌体可以消除特定的病原体,但在治疗中面临稳定性挑战.
研究的目的:
- 审查IBD治疗和挑战方面的进展.
- 探索菌体作为IBD潜在的微生物组调节器.
- 详细介绍IBD中菌体治疗的封装和向输送系统.
主要方法:
- 对当前IBD疗法和菌体应用的文献综述.
- 对菌体与IBD肠道微生物群相互作用的分析.
- 对细菌菌体的封装和向输送系统的检查.
主要成果:
- 菌体可以专门准和消除肠道微生物群中的病原体.
- 封装和有针对性的输送系统可以增强菌体的稳定性,保护感染力,并确保结肠特定的输送.
- 这些策略解决了IBD当前菌体治疗的局限性.
结论:
- 细菌体通过调节肠道微生物群来代表IBD的一个有希望的治疗策略.
- 改善菌体的稳定性和输送对于在IBD治疗中有效的临床应用至关重要.
- 本综述为开发IBD的先进细菌基疗法提供了基础.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Lytic Cycle of Bacteriophages
70.6K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
70.6K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Inflammatory Bowel Disease V: Surgical Management
144
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
144
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131


